Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | The Hokusai VTE-Cancer Study: objectives and design

Harry Buller • 10 Dec 2017
ASH 2017
General Edoxaban Heparin
HOKUSAI-VTE

What were the objectives of the Hokusai venous thromboembolism (VTE)-Cancer Study? In this interview, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, highlights the major components, objectives and findings of the trial (NCT02073682), which compared two regimens, subcutaneous injection of low-molecular-weight heparin (LMWH) and oral administration of edoxaban. Prof. Buller discusses various elements of the trial, including focusing on the composite of first recurrence or the first major bleed from VTE and continuing treatment beyond 6 months. Describing the LMWH treatment as noninferior to oral edoxaban, Prof. Buller explains the advantages of edoxaban for patients with cancer-associated VTE. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Harry Buller

1:02
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
Harry Buller • 10 Dec 2017
2:27
The Hokusai VTE-Cancer Study: the importance of improving VTE treatment
Harry Buller • 10 Dec 2017

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals